ArticleBMC pharmacology & toxicology2025
Deciphering bisphenol A (BPA)-elicited osteoarthritis mechanisms through network toxicology and molecular docking, then de novo generation of novel therapeutic candidates.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrative Network Pharmacology and Molecular Docking Analysis Reveals the Multitarget Mechanisms of Pterostilbene in Neurodegenerative Diseases.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Deciphering the potential pathogenic mechanisms of 3-BHA in ovarian cancer through integrated bioinformatics and machine learning strategies.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveBisphenol A (BPA), a pervasive environmental pollutant, is increasingly associated with osteoarthritis (OA) development, yet its molecular mechanisms remain unknown. Currently, there is no definitive cure for OA.
methodsBPA targets were predicted using STITCH and Swiss Target Prediction, while OA-related targets were collected from GeneCards, OMIM, and the Therapeutic Target Database (TTD). Protein-protein interaction (PPI) networks were constructed using STRING and visualized in Cytoscape to identify hub targets. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed, and molecular docking with AutoDock evaluated BPA-core target interactions. We employed our Computational Analysis of Novel Drug Opportunities (CANDO) platform for de novo drug prediction.
resultsSystematic bioinformatics analysis identified 26 candidate targets, with ESR1, PTGS2, CCL2, FLNA, and TRPV1 as key hubs. Pathway analysis revealed involvement in calcium ion transport, muscle contraction, IL-17 signaling, and estrogen signaling. Molecular docking confirmed strong BPA-target binding affinities. CANDO predicted 14 potential OA treatments, including glucosamine, ibuprofen, celecoxib, indomethacin, palmitic acid, and linoleic acid. Notably, qRT-PCR validation revealed that ESR1, PTGS2, CCL2, and TRPV1 were highly expressed, whereas FLNA was expressed at lower levels in the osteoarthritis blood samples.
conclusionsThis study elucidates BPA's molecular mechanisms in OA and identifies promising therapeutic candidates. The integration of network toxicology, molecular docking, and computational drug discovery provides a robust framework for understanding environmental toxicants and advancing OA therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.